Last reviewed · How we verify

Levobupivacaine PCA group

Osijek University Hospital · FDA-approved active Small molecule

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. Used for Postoperative pain management via patient-controlled analgesia (PCA), Regional anesthesia and analgesia.

At a glance

Generic nameLevobupivacaine PCA group
Also known asPostoperative continuous wound infiltration analgesia with local anesthetic, Chirocaine 0.5%
SponsorOsijek University Hospital
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Levobupivacaine is the S-enantiomer of bupivacaine, a long-acting amide local anesthetic. It works by reversibly binding to and blocking voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and conduction of nerve impulses. When administered via patient-controlled analgesia (PCA), it provides regional anesthesia and postoperative pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: